International	international	O	O
mexiletine	mexiletine	O	O
and	and	O	O
placebo	placebo	O	O
antiarrhythmic	antiarrhythmic	O	O
coronary	coronary	O	O
trial	trial	O	O
:	:	O	O
I.	i.	O	O
Report	report	O	O
on	on	O	O
arrhythmia	arrhythmia	O	S_disease
and	and	O	O
other	other	O	O
findings	findings	O	O
.	.	O	O

Impact	impact	O	O
Research	research	O	O
Group	group	O	O
.	.	O	O

The	the	O	O
antiarrhythmic	antiarrhythmic	O	O
effects	effects	O	O
of	of	O	O
the	the	O	O
sustained	sustained	B_chemicals	O
release	release	I_chemicals	O
form	form	O	O
of	of	O	O
mexiletine	mexiletine	O	O
(	(	O	O
Mexitil-Perlongets	mexitil-perlongets	O	O
)	)	O	O
were	were	O	O
evaluated	evaluated	O	O
in	in	O	O
a	a	O	O
double-blind	double-blind	O	O
placebo	placebo	O	O
trial	trial	O	O
in	in	O	O
630	630	O	O
patients	patients	O	O
with	with	O	O
recent	recent	O	O
documented	documented	O	O
myocardial	myocardial	O	B_disease
infarction	infarction	O	S_disease
.	.	O	O

The	the	O	O
primary	primary	O	O
response	response	O	O
variable	variable	O	O
was	was	O	O
based	based	O	O
on	on	O	O
central	central	O	O
reading	reading	O	O
of	of	O	O
24	24	O	O
hour	hour	O	O
ambulatory	ambulatory	O	O
electrocardiographic	electrocardiographic	O	O
recordings	recordings	O	O
and	and	O	O
was	was	O	O
defined	defined	O	O
as	as	O	O
the	the	O	O
occurrence	occurrence	O	O
of	of	O	O
30	30	O	O
or	or	O	O
more	more	O	O
single	single	O	O
premature	premature	O	O
ventricular	ventricular	O	O
complexes	complexes	O	O
in	in	O	O
any	any	O	O
two	two	O	O
consecutive	consecutive	O	O
30	30	O	O
minute	minute	O	O
blocks	blocks	O	O
or	or	O	O
one	one	O	O
or	or	O	O
more	more	O	O
runs	runs	O	O
of	of	O	O
two	two	O	O
or	or	O	O
more	more	O	O
premature	premature	O	O
ventricular	ventricular	O	O
complexes	complexes	O	O
in	in	O	O
the	the	O	O
entire	entire	O	O
24	24	O	O
hour	hour	O	O
electrocardiographic	electrocardiographic	O	O
recording	recording	O	O
.	.	O	O

Large	large	O	O
differences	differences	O	O
,	,	O	O
regarded	regarded	O	O
as	as	O	O
statistically	statistically	O	O
significant	significant	O	O
,	,	O	O
between	between	O	O
the	the	O	O
mexiletine	mexiletine	O	O
and	and	O	O
placebo	placebo	O	O
groups	groups	O	O
were	were	O	O
noted	noted	O	O
in	in	O	O
that	that	O	O
end	end	B_chemicals	O
point	point	I_chemicals	O
at	at	O	O
months	months	O	O
1	1	O	O
and	and	O	O
4	4	O	O
,	,	O	O
but	but	O	O
only	only	O	O
trends	trends	O	O
were	were	O	O
observed	observed	O	O
at	at	O	O
month	month	O	O
12	12	O	O
.	.	O	O

These	these	O	O
differences	differences	O	O
were	were	O	O
observed	observed	O	O
even	even	O	O
though	though	O	O
the	the	O	O
serum	serum	O	O
mexiletine	mexiletine	O	O
levels	levels	O	O
obtained	obtained	O	O
in	in	O	O
this	this	O	O
study	study	O	O
were	were	O	O
generally	generally	O	O
lower	lower	O	O
than	than	O	O
those	those	O	O
observed	observed	O	O
in	in	O	O
studies	studies	O	O
that	that	O	O
have	have	O	O
used	used	O	O
the	the	O	O
regular	regular	O	O
form	form	O	O
of	of	O	O
the	the	O	O
drug	drug	S_chemicals	O
.	.	O	O

There	there	O	O
were	were	O	O
more	more	O	O
deaths	deaths	O	O
in	in	O	O
the	the	O	O
mexiletine	mexiletine	O	O
group	group	O	O
(	(	O	O
7.6	7.6	O	O
%	%	O	O
)	)	O	O
than	than	O	O
in	in	O	O
the	the	O	O
placebo	placebo	O	O
group	group	O	O
(	(	O	O
4.8	4.8	O	O
%	%	O	O
)	)	O	O
;	;	O	O
the	the	O	O
difference	difference	O	O
was	was	O	O
not	not	O	O
statistically	statistically	O	O
significant	significant	O	O
.	.	O	O

The	the	O	O
incidence	incidence	O	O
of	of	O	O
coronary	coronary	O	O
events	events	O	O
was	was	O	O
similar	similar	O	O
in	in	O	O
both	both	O	O
groups	groups	O	O
.	.	O	O

Previously	previously	O	O
recognized	recognized	O	O
side	side	O	B_disease
effects	effects	O	I_disease
,	,	O	O
particularly	particularly	O	O
tremor	tremor	O	S_disease
and	and	O	O
gastrointestinal	gastrointestinal	O	O
problems	problems	O	O
,	,	O	O
were	were	O	O
more	more	O	O
frequent	frequent	O	O
in	in	O	O
the	the	O	O
mexiletine	mexiletine	O	O
group	group	O	O
than	than	O	O
in	in	O	O
the	the	O	O
placebo	placebo	O	O
group	group	O	O
.	.	O	O

